Impact of multivessel disease on infarct size among STEMI patients undergoing primary angioplasty

Atherosclerosis

Volumn 234, Issue 1, 2014, Pages 244-248

  De Luca, Giuseppe ^a   Parodi, Guido ^b   Sciagrà, Roberto ^c   Bellandi, Benedetta ^b   Comito, Vincenzo ^b   Vergara, Ruben ^b   Migliorini, Angela ^b   Valenti, Renato ^b   Antoniucci, David ^b  

^a MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Infarct size; Multivessel disease; Primary angioplasty; Smoking; STEMI

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; GLYCERYL TRINITRATE; HEPARIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; TICLOPIDINE;

ADULT; AGE; AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIAC PATIENT; CARDIOGENIC SHOCK; CLINICAL TRIAL; DISEASE ASSOCIATION; FEMALE; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HUMAN; INTRAAORTIC BALLOON PUMP; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); ST SEGMENT ELEVATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURVIVAL; TRANSLUMINAL CORONARY ANGIOPLASTY; COMPLICATION; CORONARY ARTERY DISEASE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATHOLOGY; PERCUTANEOUS CORONARY INTERVENTION;

AGED; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES;

EID: 84897942119     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.02.031     Document Type: Article

References (38)

1. De Luca G., Cassetti E., Marino P. Percutaneous coronary intervention-related time delay, patient's risk profile, and survival benefits of primary angioplasty vs lytic therapy in ST-segment elevation myocardial infarction. Am J Emerg Med 2009, 27:712-719.
2. De Luca G., Suryapranata H., Marino P. Reperfusion strategies in acute ST-elevation myocardial infarction: an overview of current status. Prog Cardiovasc Dis 2008, 50:352-382.
3. De Luca G., Cassetti E., Verdoia M., Marino P. Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty: a meta-analysis of randomised trials. Thromb Haemost 2009, 102:428-436.
4. Antoniucci D., Migliorini A., Parodi G., et al. Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone. Circulation 2004, 109:1704-1706.
5. Di Lorenzo E., De Luca G., Sauro R., et al. The PASEO (paclitaxel or sirolimus-eluting stent versus bare metal stent in primary angioplasty) randomized trial. JACC Cardiovasc Interv 2009, 2:515-523.
6. De Luca G., Navarese E.P., Suryapranata H. Ameta-analytic overview of thrombectomy during primary angioplasty. Int J Cardiol 2013, 166:606-612.
7. Capozzolo C., Piscione F., De Luca G., et al. Direct coronary stenting: effect on coronary blood flow, immediate and late clinical results. Catheter Cardiovasc Interv 2001, 53:464-473.
8. Costantini C.O., Stone G.W., Mehran R., et al. Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. JAm Coll Cardiol 2004, 44:305-312.
9. De Luca G., van 't Hof A.W., Ottervanger J.P., et al. Unsuccessful reperfusion in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. Am Heart J 2005, 150:557-562.
10. Muller D.W., Topol E.J., Ellis S.G., Sigmon K.N., Lee K., Califf R.M. Multivessel coronary artery disease: a key predictor of short-term prognosis after reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Am Heart J 1991, 121:1042-1049.
11. Jaski B.E., Cohen J.D., Trausch J., et al. Outcome of urgent percutaneous transluminal coronary angioplasty in acute myocardial infarction: comparison of single-vessel versus multivessel coronary artery disease. Am Heart J 1992, 124:1427-1433.
12. De Luca G., Suryapranata H., van 't Hof A.W., et al. Prognostic assessment of patients with acute myocardial infarction treated with primary angioplasty: implications for early discharge. Circulation 2004, 109:2737-2743.
13. Kahn J.K., Rutherford B.D., McConahay D.R., et al. Results of primary angioplasty for acute myocardial infarction in patients with multivessel coronary artery disease. JAm Coll Cardiol 1990, 16:1089-1096.
14. Goldstein J.A., Demetriou D., Grines C.L., Pica M., Shoukfeh M., O'Neill W.W. Multiple complex coronary plaques in patients with acute myocardial infarction. NEngl J Med 2000, 343:915-922.
15. Parodi G., Sciagrà R., Migliorini A., et al. Arandomized trial comparing clopidogrel with ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy. Am Heart J 2005, 150:220.
16. Migliorini A., Stabile A., Rodriguez A.E., et al. Comparison of AngioJet rheolytic thrombectomy before direct infarct artery stenting with direct stenting alone in patients with acute myocardial infarction: the JETSTENT trial. JAm Coll Cardiol 2010, 56:1298-1306.
17. De Luca G., Parodi G., Sciagrà R., et al. Time-to-treatment and infarct size in STEMI patients undergoing primary angioplasty. Int J Cardiol 2013, 167:1508-1513.
18. Cohen M., Rentrop K.P. Limitation of myocardial ischemia by collateral circulation during sudden controlled coronary artery occlusion in human subjects: a prospective study. Circulation 1986, 74:469-476.
19. O'Connor M.K., Hammel T., Gibbons R.J. Invitro validation of a simple tomographic technique for estimation of percentage myocardium at risk using methoxyisobutyl isonitrile technetium 99m (sestamibi). Eur J Nucl Med 1990, 17:69-76.
20. De Luca G., van 't Hof A.W., Ottervanger J.P., et al. Ageing, impaired myocardial perfusion, and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. Eur Heart J 2005, 26:662-666.
21. De Luca G., Gibson C.M., Bellandi F., et al. Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors. Atherosclerosis 2009, 207:181-185.
22. De Luca G., Małek L.A., Maciejewski P., et al. Impact of diabetes on survival in patients with ST-segment elevation myocardial infarction treated by primary angioplasty: insights from the POLISH STEMI registry. Atherosclerosis 2010, 210:516-520. STEMI 2003 Registry Collaborators.
23. De Luca G., Dirksen M.T., Spaulding C., et al. Impact of diabetes on long-term outcome after primary angioplasty: insights from the DESERT cooperation. Diabetes Care 2013, 36:1020-1025. DESERT Cooperation.
24. Sorajja P., Gersh B.J., Cox D.A., et al. Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Eur Heart J 2007, 28:1709-1716.
25. De Luca G., Gibson M., Cutlip D., et al. Impact of multivessel disease on myocardial perfusion and survival among patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitors. Arch Cardiovasc Dis 2013, 106:155-161. EGYPT Cooperation.
26. Dziewierz A., Siudak Z., Rakowski T., Zasada W., Dubiel J.S., Dudek D. Impact of multivessel coronary artery disease and noninfarct-related artery revascularization on outcome of patients with ST-elevation myocardial infarction transferred for primary percutaneous coronary intervention (from the EUROTRANSFER Registry). Am J Cardiol 2010, 106:342-347.
27. Tarantini G., Napodano M., Gasparetto N., et al. Impact of multivessel coronary artery disease on early ischemic injury, late clinical outcome, and remodeling in patients with acute myocardial infarction treated by primary coronary angioplasty. Coron Artery Dis 2010, 21:78-86.
28. Eitel I., Hintze S., de Waha S., et al. Prognostic impact of hyperglycemia in nondiabetic and diabetic patients with ST-elevation myocardial infarction: insights from contrast-enhanced magnetic resonance imaging. Circ Cardiovasc Imaging 2012, 5:708-718.
29. de Waha S., Desch S., Eitel I., et al. Relationship and prognostic value of microvascular obstruction and infarct size in ST-elevation myocardial infarction as visualized by magnetic resonance imaging. Clin Res Cardiol 2012, 101:487-495.
30. de Waha S., Desch S., Eitel I., et al. Impact of early vs. late microvascular obstruction assessed by magnetic resonance imaging on long-term outcome after ST-elevation myocardial infarction: a comparison with traditional prognostic markers. Eur Heart J 2010, 31:2660-2668.
31. Di Mario C., Mara S., Flavio A., et al. Single vs multivessel treatment during primary angioplasty: results of the multicentre randomised HEpacoat for cuLPrit or multivessel stenting for Acute Myocardial Infarction (HELP AMI) Study. Int J Cardiovasc Interv 2004, 6:128-133.
32. Politi L., Sgura F., Rossi R., et al. A randomized trial of target-vessel versus multivessel revascularization in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up. Heart 2010, 96:662-667.
33. Navarese E.P., De Servi S., Buffon A., Suryapranata H., De Luca G. Clinical impact of simultaneous complete revascularization vs. culprit only primary angioplasty in patients with st-elevation myocardial infarction and multivessel disease: a meta-analysis. JThromb Thrombolysis 2011, 31:217-225.
34. Kornowski R., Mehran R., Dangas G., et al. Prognostic impact of staged versus "one-time" multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. JAm Coll Cardiol 2011, 58:704-711. HORIZONS-AMI Trial Investigators.
35. Wald D.S., Morris J.K., Wald N.J., et al. Randomized trial of preventive angioplasty in myocardial infarction. NEngl J Med 2013, 369:1115-1123. PRAMI Investigators.
36. 99mTc-sestamibi defect size. Circulation 1993, 88:2224-2234.
37. De Luca G., Gibson C.M., Huber K., et al. Association between advanced Killip class at presentation and impaired myocardial perfusion among patients with ST-segment elevation myocardial infarction treated with primary angioplasty and adjunctive glycoprotein IIb-IIIa inhibitors. Am Heart J 2009, 158:416-421. EGYPT Cooperation.
38. De Luca G., van 't Hof A.W., de Boer M.J., et al. Impaired myocardial perfusion is a major explanation of the poor outcome observed in patients undergoing primary angioplasty for ST-segment-elevation myocardial infarction and signs of heart failure. Circulation 2004, 109:958-961.